AnaptysBio, Inc. (ANAB)

Market Cap	701.61M
Revenue (ttm)	111.87M
Net Income (ttm)	-140.62M
Shares Out	29.38M
EPS (ttm)	-4.79
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	614,654
Open	22.53
Previous Close	22.65
Day's Range	22.53 - 24.60
52-Week Range	12.21 - 41.31
Beta	-0.27
Analysts	Buy
Price Target	44.25 (+85.3%)
Earnings Date	Aug 4, 2025

About ANAB

AnaptysBio, Inc., a clinical-stage biotechnology company, focuses in delivering immunology therapeutics. Its products include Rosnilimab, an IgG1 antibody that targets PD-1+ T cells, resulting in their agonism or depletion, broadly impacting pathogenic drivers of autoimmune and inflammatory diseases; and ANB032, a non-depleting antibody that binds to the BTLA checkpoint receptor and inhibits activated T cell proliferation; ANB033, a novel anti-CD122 antagonist antibody that targets the shared common beta subunit of the receptors for IL-15 and I...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Jan 26, 2017
• Employees: 136
• Stock Exchange: NASDAQ
• Ticker Symbol: ANAB
• Website: https://www.anaptysbio.com

Financial Performance

In 2024, AnaptysBio's revenue was $91.28 million, an increase of 432.03% compared to the previous year's $17.16 million. Losses were -$145.23 million, -11.24% less than in 2023.

Analyst Summary

According to 10 analysts, the average rating for ANAB stock is "Buy." The 12-month stock price target is $44.25, which is an increase of 85.30% from the latest price.

Price Target

$44.25

(85.30% upside)

Analyst Consensus: Buy